Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms
05:07pm, Tuesday, 16'th Jun 2026
Tempus AI (TEM) has consolidated near trend lows for four months, forming a double bottom with breakout resistance at $54.75 and a first target near $64.54.
Tempus AI: AI Precision Medicine With A Moat
11:32am, Thursday, 11'th Jun 2026
Tempus AI trades at multi-year lows despite proprietary data advantages and robust AI-driven precision medicine capabilities. The company leverages 500+ petabytes of unique multimodal healthcare data
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
08:30am, Thursday, 11'th Jun 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation
Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy
07:38am, Tuesday, 09'th Jun 2026
Tempus AI (TEM) now offers an attractive risk-reward setup, with valuations normalized to ~5.7x forward revenue and improved visibility on durable, high-margin revenues. Organic growth remains robust
Tempus AI: A Unique AI Business Model With Asymmetric Upside
06:36am, Tuesday, 09'th Jun 2026
Tempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI. TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrati
Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
04:58pm, Monday, 08'th Jun 2026
Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner
02:30pm, Monday, 08'th Jun 2026
Tempus AI is growing fast, but the real debate is whether its healthcare data platform can justify the premium price investors are already paying.
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
04:01pm, Friday, 05'th Jun 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
12:00am, Friday, 05'th Jun 2026
Oura Ring's IPO looks like Peloton in 2020 - great product, dangerous price. Ten public wellness stocks own the real trade.
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report?
12:35pm, Thursday, 04'th Jun 2026
Tempus (TEM) reported earnings 30 days ago. What's next for the stock?
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
08:30am, Wednesday, 03'rd Jun 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Canc
AI News You Need to Know — June Edition: Capex, Inference, & Beyond
07:37am, Wednesday, 03'rd Jun 2026
The AI trade keeps broadening across the stack, and the last few weeks have delivered a dense run of news.
Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript
07:32am, Wednesday, 03'rd Jun 2026
Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
08:30am, Monday, 01'st Jun 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next
